How AI Drug Discovery is Supercharging Pace of Innovation with Tom Miller Co-Founder & CEO of Iambic

Explore the future of drug development with AI that could compress decades of research into just years! Joining us at Catalio Conversations is Tom Miller, co-founder of Iambic, where he reveals how combining cutting-edge neural models with high-throughput experimentation is rewriting the rules of pharmaceutical innovation – think a cancer drug designed, optimized, and FDA-approved in under two years!Tom's journey from Caltech professor to drug discovery entrepreneur – alongside co-founder Fred Manby – offers a masterclass in turning academic breakthroughs into real-world medicines. From Iambic's game-changing Neuroplexer model that predicts exactly how drugs bind to proteins, to their landmark cancer candidate IM1363, this episode pulls back the curtain on what genuinely AI-powered drug discovery looks like. And with strategic partnerships with Lundbeck, Revolution Medicines, and Takeda already in place, Iambic isn't just promising the future – they're building it.Perfect for life sciences leaders, AI enthusiasts, and anyone curious about the next frontier of medicine, this episode reveals the paradigm shifts redefining what's possible in pharma. Don't miss this front-row seat to the biggest leap in pharmaceutical history – the next blockbuster cancer drug might already be designed by an algorithm, waiting to save your life.Timestamped Summary: 00:00 - Introduction to Catalio Conversations and guest Tom Miller00:29 - Tom’s journey from Caltech professor to drug innovator01:28 - Collaboration with co-founder Fred Manby01:55 - Balancing scientific integrity with entrepreneurial agility02:21 - Lessons from early Iambic experiments03:13 - AI prediction and high-throughput experimentation03:43 - Defining drug targets and designing molecules04:11 - Neuroplexer in predicting drug-protein binding05:06 - Multi-property optimization in discovery06:24 - Rapid development of cancer candidate IM136306:49 - AI reducing drug development timelines07:16 - Industry impact of AI-designed medicines07:59 - Partnerships with Lundbeck and Revolution Medicines08:55 - Building credibility through collaborations09:21 - Genuine AI transformation vs. superficial branding09:45 - Scaling advantage of AI-powered discovery10:36 - AI’s potential in biological complexity11:31 - Future of AI in drug development12:24 - Iambic’s identity: AI platform or drug company?13:21 - Future goals for Iambic and industry impact14:13 - Promising targets like transcription factors14:42 - Closing remarks and encouragement for innovation